How Much Did Maze Therapeutics Raise? Funding & Key Investors

Maze Therapeutics has successfully raised funds through five funding rounds, with the latest being a Post-IPO Equity round. The company is backed by 21 investors, including Deep Track Capital and Venrock Healthcare Capital Partners.

Keep reading to explore the intricacies of Maze Therapeutics' fundraising journey and the investors backing this innovative biotechnology company.

What Is Maze Therapeutics?

Maze Therapeutics is a biotechnology company based in South San Francisco, California. The company focuses on developing precision medicines for renal, cardiovascular, and metabolic diseases, leveraging advances in human genetics and its proprietary Compass platform.

With an employee count ranging between 101-250, Maze Therapeutics is committed to addressing large unmet medical needs. The company has made significant strides, including successful financing rounds and positive trial results for its lead programs.

How Much Funding Has Maze Therapeutics Raised?

1. Series A
   • Amount Raised: USD 191,000,000
   • Date: February 2019
   • Lead Investors: ARCH Venture Partners, Third Rock Ventures
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To support the company's mission of translating genetic insights into new medicines.
2. Series Unknown
   • Amount Raised: Not publicly disclosed
   • Date: October 2019
   • Lead Investors: City Hill Ventures
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: Likely to expand research and development capabilities.
3. Series Unknown
   • Amount Raised: USD 190,000,000
   • Date: January 2022
   • Lead Investors: Matrix Capital Management
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To advance clinical trials and scale operations.
4. Series D
   • Amount Raised: USD 115,000,000
   • Date: December 2024
   • Lead Investors: Deep Track Capital, Frazier Life Sciences
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To further develop precision medicines and expand market reach.
5. Post-IPO Equity
   • Amount Raised: USD 150,000,000
   • Date: September 2025
   • Lead Investors: Not publicly disclosed
   • Valuation at Round: Not publicly disclosed
   • Motivation Behind the Round: To support ongoing research and commercialization efforts.

Total Amount Raised: USD 646,000,000. Current Valuation: Not publicly disclosed.

Key Investors

• Third Rock Ventures
  • Details: Third Rock Ventures is a venture capital firm that focuses on building and launching companies in the life sciences sector.
  • Investment Focus Areas: Life sciences, biotechnology, healthcare
  • Notable Investments: Bluebird Bio, Editas Medicine, Foundation Medicine
• ARCH Venture Partners
  • Details: ARCH Venture Partners is a venture capital firm that invests in the development of seed and early-stage advanced technology companies.
  • Investment Focus Areas: Advanced technology, life sciences, biotechnology
  • Notable Investments: Illumina, Alnylam Pharmaceuticals, Juno Therapeutics
• GV (formerly Google Ventures)
  • Details: GV is the venture capital investment arm of Alphabet Inc., providing seed, venture, and growth-stage funding to technology companies.
  • Investment Focus Areas: Technology, life sciences, healthcare, artificial intelligence
  • Notable Investments: Uber, Slack, Flatiron Health
• Foresite Capital
  • Details: Foresite Capital is a healthcare and life sciences investment firm that provides growth capital to emerging healthcare leaders.
  • Investment Focus Areas: Healthcare, life sciences, biotechnology, medical technology
  • Notable Investments: Denali Therapeutics, Relay Therapeutics, 10x Genomics
• Casdin Capital
  • Details: Casdin Capital is an investment firm focused on the life sciences and healthcare sectors.
  • Investment Focus Areas: Life sciences, healthcare, biotechnology
  • Notable Investments: Twist Bioscience, Tango Therapeutics, Sema4

What's Next for Maze Therapeutics?

Maze Therapeutics stands at the forefront of genetic medicine, leveraging its substantial $191 million launch funding to translate genetic insights into new medicines. The company's focus on complex diseases and genetic disorders presents a significant opportunity for growth, supported by the expertise of renowned scientists and high-profile investors.

Future fundraising opportunities appear promising as Maze Therapeutics progresses in its research and development. The initial investor confidence suggests potential for additional investments, which could further bolster the company's efforts in advancing clinical trials and scaling operations.

However, the path ahead is not without challenges. High research and development costs, regulatory hurdles, and competition from other biotech companies are significant obstacles. Yet, with a strong foundation and a clear vision, Maze Therapeutics is well-positioned to navigate these challenges and make impactful advancements in genetic medicine.

Use Clay to Get Funding Data

Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Maze Therapeutics and gather other critical business insights.

Sign up for free to start exploring the wealth of information available at your fingertips.